Biogen Provides Regulatory Update on High-Dose Nusinersen Regimen
Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the company’s supplemental New Drug Application (sNDA) for…
Read More...
Read More...
